


Product Data Sheet

Zelavespib

Cat. No.:	A3739
CAS No.:	873436-91-0
Formula:	C ₁₉ H ₂₃ N ₆ O ₄ S
M.Wt:	512.37
Synonyms:	PU-H71, NSC 750424
Target:	HSP
Pathway:	Proteases
Storage:	Store at -20° C



Solvent & Solubility

Soluble in DMSO > 10 mM

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	Concentration			
	1 mM	1.9517 mL	9.7586 mL	19.5171 mL
	5 mM	0.3903 mL	1.9517 mL	3.9034 mL
	10 mM	0.1952 mL	0.9759 mL	1.9517 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

An effective heat shock protein 90 (Hsp90) inhibitor.

IC₅₀ & Target

51 nM (in MDA-MB-468 cell line) (Hsp90)

In Vitro

Cell Viability Assay

Cell Line: Human triple-negative breast cancers (TNBC) cell lines MDA-MB-468, MDA-MB-231 and HCC-1806

Preparation method: The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

	Reacting conditions:	0.01 ~ 10 μ M; 72 hrs
	Applications:	In TNBC cell lines MDA-MB-468, MDA-MB-231 and HCC-1806, PU-H71 (1 μ M) potently suppressed cell growth, with the IC50 values of 65, 140 and 87 nM, respectively. PU-H71 (1 μ M) killed 80%, 65%, and 80% of the initial population of MDA-MB-468, MDA-MB-231 and HCC-1806 cells, respectively.
In Vivo	Animal experiment	
	Animal models:	Mice bearing MDA-MB-231 xenografted tumors
	Dosage form:	75 mg/kg; i.p.; on an alternate day schedule, for 50 days
	Applications:	In the MDA-MB-231 model, PU-H71 (75 mg/kg on an alternate day schedule) induced a 100% complete response, and tumors were reduced to scar tissue after 37 days of treatment, accompanied with reduction in many proliferative and anti-apoptotic molecules, namely 80%, 95%, 99%, 80% and 65% decreases in EGFR, HER3, Raf-1 Akt, and p-Akt, respectively.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1. Crowe LB, Hughes PF, et al. "A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo." ACS Chem Biol. 2017 Apr 21;12(4):1047-1055. PMID:28103010

See more customer validations on www.apexbt.com.

References

[1]. Caldas-Lopes E, Cerchietti L, Ahn J H, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences, 2009, 106(20): 8368-8373.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 422, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

